EDSA Stock — Edesa Biotech Inc. Common Shares: Cash, EV, Pipeline

Share price

$4.14

Market cap

$55.9M

Cash

$33.4M

Enterprise value

$22.5M

Balance sheet

Cash	$33.4M
Debt	$0.0M
Net cash	$33.4M
Enterprise value	$22.5M
Basic shares	9.6M shares
Fully diluted shares	16.7M shares
Fully diluted market cap	$69.0M
Cash per share	$3.48

Cash figures as of 2026-08-21. Database snapshot: 2026-09-21.

Price history

Loading EDSA daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Aug 12 - Sep 23	Cohort C: bevacizumab	Phase 2	Acute Respiratory Distress Syndrome (ARDS); ARDS; ARDS (Acute Respiratory Distress Syndrome)	—
Aug 12 - Sep 23	Cohort B: paridiprubart	Phase 2	Acute Respiratory Distress Syndrome (ARDS); ARDS; ARDS (Acute Respiratory Distress Syndrome)	—
Aug 12 - Sep 23	Cohort A: vilobelimab	Phase 2	Acute Respiratory Distress Syndrome (ARDS); ARDS; ARDS (Acute Respiratory Distress Syndrome)	—
Aug 12 - Sep 23	Cohort A: vilobelimab	Phase 2	Acute Respiratory Distress Syndrome (ARDS); ARDS; ARDS (Acute Respiratory Distress Syndrome)	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

EB06

Phase 2 · Active Modality: monoclonal antibody

Target CXCL10

Partnerships Unnamed pharmaceutical development company: exclusive worldwide license to monoclonal antibody Constructs incl. sublicensing rights (Apr 2020; 25-year term from first commercial sale)

Indications

Vitiligo (moderate-to-severe nonsegmental) (Phase 2)

Status note Health Canada approved Phase 2 proof-of-concept study in vitiligo; CMC information being provided to FDA in connection with IND. Manufacturing preparations for planned Phase 2 underway.

Paridiprubart

Phase 3 · Active

Aliases EB05

Target TLR4

Partnerships Government of Canada Strategic Response Fund: up to C$23M partially repayable funding (Oct 2023, amended Sep 2025) for Phase 3 completion, approval submissions, manufacturing scale-up and two non-clinical safety studies

Indications

Acute respiratory distress syndrome (ARDS) (Phase 3)

Status note Phase 3 study in hospitalized ARDS patients reported Oct 2025; being evaluated in an ongoing U.S. government-funded ARDS platform study.

Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06701656	Phase 2	Recruiting	Collaborator	PPD Development, LP	—	Acute Respiratory Distress Syndrome (ARDS); ARDS; ARDS (Acute Respiratory Distress Syndrome)	—
NCT06701669	Phase 2	Recruiting	Collaborator	PPD Development, LP	—	Acute Respiratory Distress Syndrome (ARDS); ARDS; ARDS (Acute Respiratory Distress Syndrome)	—
NCT06701682	Phase 2	Recruiting	Collaborator	PPD Development, LP	—	Acute Respiratory Distress Syndrome (ARDS); ARDS; ARDS (Acute Respiratory Distress Syndrome)	—
NCT06703073	Phase 2	Recruiting	Collaborator	PPD Development, LP	—	Acute Respiratory Distress Syndrome (ARDS); ARDS; ARDS (Acute Respiratory Distress Syndrome)	—

Sponsor-matched active trials from ClinicalTrials.gov (0 as sponsor, 4 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 4 active trials for PPD Development, LP on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

EDSA — Edesa Biotech Inc. Common Shares

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Active clinical trials